Epic Research: ADHD Medications Prescribed at Similar Rates During Telehealth and In-Person Visits

Epic Research: ADHD Medications Prescribed at Similar Rates During Telehealth and In-Person Visits This study analyzed medication prescribing rates for telehealth and office visits, which found that attention deficit hyperactivity disorder (ADHD) medications were prescribed at similar rates during telehealth and in-person visits. Most initial ADHD prescriptions were for stimulant medications in both telehealth (84 [...]

2023-11-27T18:22:28-04:00June 27th, 2023|

Concerns Align on the DEA Telemedicine Rule

Over 35,000 Americans provided comments on the Drug Enforcement Administration's (DEA) proposed rule, "Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation." In comment letters responding to the DEA's proposed rule, hundreds of key stakeholders highlighted the need for a special registration for telemedicine and [...]

2023-04-07T13:24:26-04:00April 7th, 2023|

NEW Foley Analysis – DEA Special Registration Rule

Foley & Lardner LLP, an international law firm, released a white paper analysis, which discusses the legal authority and statutory obligation of the Drug Enforcement Administration (DEA) to promulgate regulations specifying the circumstances in which a special registration may be issued, and more.Notably, it concludes:“The recently released proposed rule does not satisfy DEA’s obligation as [...]

2023-03-21T12:14:42-04:00March 20th, 2023|

Drug Enforcement Administration Notice of Proposed Rulemaking Summary

Telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation (RIN: 1117-AB40)Drug Enforcement Administration Notice of Proposed RulemakingPublic comments due March 31, 2023DEA Resources: Rule Text Highlights for Medical PractitionersDEA Summary ChartSee companion buprenorphine rule summary hereProposed Rule OverviewThe Ryan Haight Act of 2008 directed the [...]

2023-03-16T17:43:46-04:00February 27th, 2023|

Summary of Expansion of Induction of Buprenorphine via Telemedicine Encounter

The Drug Enforcement Administration (DEA) released its Notice of Proposed Rulemaking (NPRM) on buprenorphine via telemedicine encounter, a summary, and highlights for medical practitioners. The proposed rule amends the DEA’s regulations, in concert with the Department of Health and Human Services (HHS), on the circumstances under which individual practitioners are authorized to prescribe schedule [...]

2023-03-07T14:11:03-04:00February 27th, 2023|

Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic

JAMA Network Open: Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic This study found that eased rules permitting doctors to prescribe buprenorphine to treat opioid use disorder through telemedicine during the COVID-19 pandemic didn’t result in a rise in the share of overdose deaths involving the drug. The report, from [...]

2023-04-24T11:02:47-04:00January 20th, 2023|
Go to Top